PRESCRIPTION DRUGS: Senator Praises Inhalation-Drug Pricing Plan

Article Overview

This article covers a CMS proposal to change Medicare reimbursement for compounded inhalation drugs and the policy reaction from a U.S. senator, pharmacy representatives, and a compounding-pharmacy organization. It is relevant to suppliers, pharmacies, home health stakeholders, and compliance or reimbursement readers monitoring Medicare payment policy, compounded-drug oversight, and patient-access concerns. The discussion stays at a high level and focuses on the general direction of the proposed changes, stakeholder responses, and broader safety and oversight issues.